Compare ARK Genomic Revolution ETF (ARKG) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs RLX Technology Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.62, while RLX Technology Inc trades at $2.02 (market cap $2.42B). The key difference: RLX Technology Inc pays a 5.05% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, RLX Technology Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | RLX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $44.55 | $2.73 |
52-Week Low | $24.02 | $1.79 |
Market Cap | — | $2.42B |
Enterprise Value | — | $1.04B |
Dividend Yield | — | 5.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.
Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.
RLX Technology trades at $2.02, up 1.0% with bearish technical signals despite recent earnings misses. The company maintains strong profitability with 22.47% net margins and international expansion driving revenue growth from $3.62B to $4.4B. Cash flow trends show operational strength but negative net cash flow. Analyst coverage remains limited with a single hold rating.
RLX faces execution risks from international integration while trading at reasonable valuations (P/E 17.96). The upcoming Q2 2026 earnings on August 14 will be crucial for validating growth trajectory amid competitive and regulatory pressures in the global e-vapor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
